Why your joints wear out, and what we are trying to do about it.
Osteoarthritis is the world's most common joint disease and one of its most stubborn — partly because cartilage, once gone, doesn't really grow back. A tour of what's happening inside an aching joint, and where the new generation of treatments fits in.
A patient walks into a clinic with knee pain. She is sixty-two. The pain came on slowly, over years, the way most chronic things do — first a little ache after long walks, then mornings of stiffness, then nights where the joint throbs in time with her pulse. She has tried glucosamine, ibuprofen, a knee brace from a friend. Now she is sitting on the exam table asking the question every orthopaedic surgeon hears, in some form, every working day.
What is actually happening inside my knee?
Here is the honest answer.
What a joint really is
A joint is, structurally, a remarkable piece of engineering. Two bones meet and slide against each other inside a sealed capsule. The ends of those bones are capped with cartilage — a glassy, almost translucent tissue, mostly water held inside a scaffold of collagen. Between the cartilage surfaces is a thin film of synovial fluid, which is itself extraordinary: under low pressure it is slippery, and under high pressure it stiffens, so the joint glides under weight without grinding.
This whole system is fed and cleaned by something most patients have never heard of: a network of tiny vessels in the surrounding tissue, half of them carrying blood, the other half carrying lymph. The lymphatic vessels are the joint’s drainage system. They pull excess fluid, dead cells, and inflammatory debris out of the joint capsule and ferry it back into circulation, where the immune system can deal with it.
When everything works, you don’t think about any of this. The whole apparatus is, in healthy young adults, almost frictionless.
What goes wrong
Osteoarthritis — OA — is what we call this whole system breaking down. For decades it was taught as a wear-and-tear disease: the cartilage gets used up, like the tread on a tyre, and once it’s gone, it’s gone. That picture is half right. Cartilage really does not regenerate the way bone does. But the reason it doesn’t is more interesting than mechanical wear.
Inside an osteoarthritic joint, the immune system is involved earlier and more deeply than we used to think. Cartilage cells — chondrocytes — start producing inflammatory signals. Macrophages, the immune system’s clean-up crew, arrive in the synovial lining. Small chemokines pull in more immune cells. The joint becomes, quietly, a low-grade inflammatory environment.
And the lymphatic vessels — those drainage pipes — start to fail.
This last part is where my own work has lived for the past few years. In a 2026 review I wrote with my colleagues for Bone Research, we surveyed the evidence on how the lymphatic system itself changes in joint disease. The pattern, across studies, is consistent: as OA progresses, lymphatic vessels in the joint capsule become less functional. Drainage slows. Inflammatory debris that should be cleared instead accumulates. The joint, in effect, stops cleaning itself, and the inflammation feeds back on the cartilage that is already struggling.
It is a vicious circle, and it is a fundamentally different way of thinking about OA than the wear-and-tear model.
Why most treatments don’t fix it
Once you understand the inflammation–drainage feedback loop, a lot of clinical experience starts to make sense.
Anti-inflammatory drugs — ibuprofen, naproxen, the COX-2 inhibitors — work in OA. They reduce pain and stiffness. They do not, in any clinical trial that has ever been run, regrow cartilage or stop the disease from progressing. They quiet the inflammation enough to make the joint usable, but the underlying drainage failure continues. Stop the drug; the pain comes back.
Hyaluronic acid injections, sometimes called “gel shots,” work similarly. They lubricate. They probably calm some inflammation. The data on long-term cartilage protection is, charitably, mixed.
Cortisone injections are even more revealing: they crush inflammation hard for a few months, and several large trials suggest they may actually accelerate cartilage loss with repeated use. A drug that works against the symptom while making the cause worse.
Joint replacement surgery is genuinely curative for the right patient — a worn-out knee or hip swapped for a metal-and-polyethylene replica. But the bar for surgery is high, and most patients spend years between “this hurts” and “this is bad enough to operate on,” with no good option in between.
That gap — between an over-the-counter painkiller and a major operation — is where the next generation of treatments is being built.
What’s coming
The active research in joint disease today is, broadly, trying to do three things at once: calm inflammation locally, restore drainage, and create conditions where what’s left of the cartilage can heal. A few of the most promising directions:
Immunomodulatory injectables. Instead of generic anti-inflammatories that suppress the whole immune system, drugs that nudge specific immune cells — particularly macrophages — from their inflammatory state into a repair state. The biology is well understood; the delivery is the hard part. You need the drug to stay in the joint long enough to work, without leaking everywhere else.
Hydrogels. Injectable, biocompatible gels that act as both a scaffold and a drug-delivery system. The hydrogel sits in the joint, releases its payload slowly over weeks, and provides some mechanical cushioning while it does. Several variants are in early human trials in 2026.
Lymphatic-directed therapy. This is newer and more speculative, but follows directly from the drainage-failure idea: drugs or interventions that promote lymphatic vessel growth or function inside the joint. Most of the published work is still preclinical, but the rationale is strong.
Senolytic and metabolic approaches. Old chondrocytes, like old cells everywhere, sometimes fail to die properly and instead sit around producing inflammatory signals. Drugs that selectively clear those cells — senolytics — are being trialled across multiple age-related diseases, including OA.
None of these are ready for routine clinical use yet. Most are five to ten years away from being in your local orthopaedic practice. But for the first time in a long time, OA looks like a disease we might actually treat — not just manage around.
What this means for the patient on the exam table
I am careful with patients about the gap between “what the science says” and “what your insurance will pay for tomorrow.” For the woman with the aching knee in 2026, the honest plan is still the boring one: lose weight if you can, build the muscles around the joint, take an anti-inflammatory when you need it, consider a steroid injection sparingly, and have a conversation about when surgery starts to make sense.
But it is no longer true, as it once was, that we have nothing better in the pipeline. Patients in their forties and fifties today may, by the time they need real intervention, have access to treatments that genuinely change the disease — not just the pain.
That is the part of this work that keeps me at the bench. Not the elegant immunology or the clever materials. The fact that, somewhere down the line, the patient with the throbbing knee gets a different answer than the one we have been giving for a hundred years.
If you want to read the underlying review on the lymphatic system in musculoskeletal disease, it is open access at Bone Research. I’ll write more on macrophage polarization in a future essay; subscribe if you’d like that in your inbox.